308 related articles for article (PubMed ID: 27469239)
1. The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
Cockburn JG; Hallett RM; Gillgrass AE; Dias KN; Whelan T; Levine MN; Hassell JA; Bane A
BMC Cancer; 2016 Jul; 16():555. PubMed ID: 27469239
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
[TBL] [Abstract][Full Text] [Related]
3. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
Wen HY; Krystel-Whittemore M; Patil S; Pareja F; Bowser ZL; Dickler MN; Norton L; Morrow M; Hudis CA; Brogi E
Cancer; 2017 Jan; 123(1):131-137. PubMed ID: 27526056
[TBL] [Abstract][Full Text] [Related]
4. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
5. Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
Buus R; Yeo B; Brentnall AR; Klintman M; Cheang MCU; Khabra K; Sestak I; Gao Q; Cuzick J; Dowsett M
Breast Cancer Res; 2018 Sep; 20(1):103. PubMed ID: 30180877
[TBL] [Abstract][Full Text] [Related]
6. Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer.
Rakha EA; Agarwal D; Green AR; Ashankyty I; Ellis IO; Ball G; Alaskandarany MA
Histopathology; 2017 Mar; 70(4):622-631. PubMed ID: 27782306
[TBL] [Abstract][Full Text] [Related]
7. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Vallon-Christersson J; Häkkinen J; Hegardt C; Saal LH; Larsson C; Ehinger A; Lindman H; Olofsson H; Sjöblom T; Wärnberg F; Ryden L; Loman N; Malmberg M; Borg Å; Staaf J
Sci Rep; 2019 Aug; 9(1):12184. PubMed ID: 31434940
[TBL] [Abstract][Full Text] [Related]
8. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
[TBL] [Abstract][Full Text] [Related]
10. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
11. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
12. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
13. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
Falck AK; Fernö M; Bendahl PO; Rydén L
World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
[TBL] [Abstract][Full Text] [Related]
14. Additional prognostic value of the 70-gene signature (MammaPrint(®)) among breast cancer patients with 4-9 positive lymph nodes.
Saghatchian M; Mook S; Pruneri G; Viale G; Glas AM; Guerin S; Cardoso F; Piccart M; Tursz T; Delaloge S; van't Veer L
Breast; 2013 Oct; 22(5):682-90. PubMed ID: 23347730
[TBL] [Abstract][Full Text] [Related]
15. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
Habel LA; Shak S; Jacobs MK; Capra A; Alexander C; Pho M; Baker J; Walker M; Watson D; Hackett J; Blick NT; Greenberg D; Fehrenbacher L; Langholz B; Quesenberry CP
Breast Cancer Res; 2006; 8(3):R25. PubMed ID: 16737553
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
18. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.
Prat A; Parker JS; Fan C; Cheang MCU; Miller LD; Bergh J; Chia SKL; Bernard PS; Nielsen TO; Ellis MJ; Carey LA; Perou CM
Ann Oncol; 2012 Nov; 23(11):2866-2873. PubMed ID: 22532584
[TBL] [Abstract][Full Text] [Related]
19. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneic expression of estrogen receptor between the primary tumor and the corresponding involved lymph nodes in patients with node-positive breast cancer and its implications in patient outcome.
Iguchi C; Nio Y; Itakura M
J Surg Oncol; 2003 Jun; 83(2):85-93. PubMed ID: 12772201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]